Botanix Pharmaceuticals Ltd (ASX: BOT) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Botanix Pharmaceuticals Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $72.99 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 973.14 million
Earnings per share -0.010
Dividend per share N/A
Year To Date Return -39.20%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of May 24th 2021

Botanix Pharmaceuticals Ltd (ASX: BOT)
Latest News

BOT ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Botanix Pharmaceuticals Ltd

Botanix Pharmaceuticals Ltd is a clinical stage cannabinoid therapeutics company. The company focus is the development of safe and effective topical treatments for serious skin conditions. It has an exclusive license to use a proprietary drug delivery system - Permetrex for direct skin delivery of active pharmaceuticals in all skin diseases. The company's product pipeline includes BTX1503 - Moderate to Severe Acne, BTX1308 - Plaque Psoriasis, BTX1204 - Atopic Dermatitis, andBTX 1701 - Mild Acne.

BOT Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
30 Jul 2021 $0.08 $0.00 0.00% 351,869 $0.08 $0.08 $0.08
29 Jul 2021 $0.08 $0.00 0.00% 1,042,970 $0.08 $0.08 $0.08
28 Jul 2021 $0.08 $0.00 0.00% 553,790 $0.08 $0.08 $0.08
27 Jul 2021 $0.08 $0.00 0.00% 1,522,464 $0.08 $0.08 $0.08
26 Jul 2021 $0.08 $0.00 0.00% 1,675,719 $0.08 $0.08 $0.08
23 Jul 2021 $0.08 $0.00 0.00% 868,514 $0.08 $0.08 $0.08
22 Jul 2021 $0.08 $0.00 0.00% 489,736 $0.08 $0.08 $0.08
21 Jul 2021 $0.08 $0.00 0.00% 580,162 $0.08 $0.08 $0.08
20 Jul 2021 $0.08 $0.00 0.00% 668,144 $0.08 $0.08 $0.08
19 Jul 2021 $0.08 $0.00 0.00% 1,612,225 $0.08 $0.08 $0.08
16 Jul 2021 $0.08 $0.00 0.00% 937,303 $0.08 $0.08 $0.08
15 Jul 2021 $0.08 $0.00 0.00% 194,542 $0.08 $0.08 $0.08
14 Jul 2021 $0.08 $0.00 0.00% 510,559 $0.08 $0.08 $0.08
13 Jul 2021 $0.08 $0.00 0.00% 1,061,512 $0.09 $0.09 $0.08
12 Jul 2021 $0.09 $0.00 0.00% 990,839 $0.09 $0.09 $0.08
09 Jul 2021 $0.08 $0.00 0.00% 633,611 $0.08 $0.09 $0.08
08 Jul 2021 $0.09 $0.00 0.00% 1,354,300 $0.09 $0.09 $0.09
07 Jul 2021 $0.09 $0.00 0.00% 1,613,389 $0.09 $0.09 $0.09
06 Jul 2021 $0.09 $0.00 0.00% 663,169 $0.09 $0.09 $0.09
05 Jul 2021 $0.09 $-0.01 -10.75% 1,637,538 $0.09 $0.09 $0.09

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Matthew (Matt) Callahan Executive Director Feb 2020
Mr Callahan is an experienced life sciences executive based in Philadelphia. He is a founder of Botanix and coinventor of many of the Company's Permetrex enabled products. Matt was the founding CEO of Churchill Pharmaceuticals and developed Yonsa through FDA approval and subsequent sale to Sun Pharmaceuticals. He was also founding CEO of drug delivery company iCeutica Inc which developed 4 FDA approved products and was sold to Iroko Pharmaceuticals. He has more than 25 years legal, IP and investment management experience.
Dr Stewart James Washer Non-Executive Director Feb 2019
Dr Washer has CEO and Board experience in medical biotech and cannabinoid companies. He is currently the Executive Chairman of Emerald Clinics, medical cannabis patient data collection and clinics.
Dr H. William Bosch Executive Director Jul 2016
Dr Bosch is a seasoned Pharmaceuticals executive with more than 25 years of experience in the industry, focusing on applications of drug delivery technology to Pharmaceuticals product development. Dr Bosch also works with iCeutica Inc. and is a co-inventor of the SoluMatrix technology and has been instrumental in the development and scale up of the platform and the development of the three FDA approved products that use that drug delivery technology.
Mr Vince Ippolito PresidentExecutive ChairmanExecutive Director May 2019
Mr Ippolito has more than 30 years of experience in the pharmaceuticals industry, including more over 20 years' experience in dermatology. He most recently served as President and Chief Operating Officer of Dermavant Sciences, a specialty biopharmaceutical company that is commercialising products which treat inflammatory skin diseases and medical dermatologic conditions. Mr Ippolito also sits on the Board of Suneva Medical, a privately held regenerative aesthetics company.
Mr Simon Lee Robertson Company Secretary Feb 2017
-
Simon Lee Robertson Company Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Shenasaby Investments Pty Ltd 70,738,307 7.27%
Caperi Pty Ltd 59,573,784 6.12%
Dr Henry William Bosch 16,000,000 1.64%
Yarraandoo Pty Ltd 10,000,000 1.03%
Sweet As Developments Pty Lt 9,815,455 1.01%
Citicorp Nominees Pty Limited 9,307,982 0.96%
Mr Ka Kian Lim 9,263,000 0.95%
Zenith Pacific Limited 9,000,000 0.93%
Zanya Nminees Pty Ld 8,584,545 0.88%
Jp Morgan Nominees Australia Pty Limited 7,756,446 0.80%
Mr Ancuan Lim 7,672,000 0.79%
HSBC Custody Nominees (Australia) Limited 7,315,893 0.75%
T T Nicholls Pty Ltd 7,000,000 0.72%
Mr Michael William Gaule 6,384,494 0.66%
Splendid Stuff Pty Ltd 6,242,156 0.64%
J & N Weston Investments Pty Ltd 5,650,000 0.58%
Mr Stephane Nicolas Fayd'Herbe 5,625,000 0.58%
BNP Paribas Nominees Pty Ltd 5,435,688 0.56%
Mr Brendan Paul Cooper 5,373,413 0.55%
Argonaut Investments Pty Ltd 5,000,000 0.51%

Profile

since

Note